Key Developments For Auxilium Pharmaceuticals, Inc.
Auxilium Pharmaceuticals, Inc. (AUXL.O) (Nasdaq)
Auxilium Pharmaceuticals, Inc. Reaffirms FY 2009 Revenue Guidance-Conference Calls
Auxilium Pharmaceuticals, Inc. reaffirmed its fiscal 2009 revenue guidance and expects net revenue to be in the range of $155-$165 million. According to Reuters Estimates, analysts are expecting the Company to report revenues of $160 million for the same period.
Auxilium Pharmaceuticals, Inc. Completes Sale Of 3.45 Million Shares
Auxilium Pharmaceuticals, Inc. announced that it has closed its public offering of 3,000,000 shares of its common stock at a price of $34.50 per share. On September 29, 2009, Jefferies & Company, acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 450,000 shares of common stock. The exercise of the option increased the size of the offering to an aggregate of 3,450,000 shares of common stock. Auxilium received proceeds, net of offering expenses and underwriting discounts and commissions, of approximately $115.7 million.
Auxilium Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock
Auxilium Pharmaceuticals, Inc. announced the pricing of a public offering of 3 million shares of its common stock. The offering is expected to close on or about September 30, 2009, subject to customary closing conditions. In addition, Auxilium has granted the underwriter a 30 day option to purchase up to an additional 450,000 shares to cover over-allotments, if any. Jefferies & Company is acting as sole book-running manager in this offering.
U.S. Food and Drug Administration's Arthritis Advisory Committee Votes Unanimously 12-0 To Recommend Approval Of Auxilium Pharmaceuticals, Inc.'s XIAFLEX
Auxilium Pharmaceuticals, Inc. announced that the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) recommended by a unanimous vote of 12 to that XIAFLEX (collagenase clostridium histolyticum), a orphan-designated, biologic, be granted marketing approval by the FDA for the treatment of Dupuytren's contracture.
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX CORD I Study Results
Auxilium Pharmaceuticals, Inc. announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), for the nonsurgical treatment of Dupuytren's contracture. The CORD I study is the prospective clinical trial ever conducted in the field of Dupuytren's contracture. Treatment with XIAFLEX significantly reduced the angle of contracture for patients with Dupuytren's contracture in both their metacarpophalangeal (MP) and proximal interphalangeal (PIP) joints, with clinically meaningful responses in both less severe and more severe contractures. Auxilium has previously announced top line results of the CORD I study, which indicate that 64.0% of all joints treated with XIAFLEX achieved the primary endpoint of 0� to 5� of full extension (normal or near normal straightening of the treated finger) at 30 days after the last injection compared to 6.8% of patients treated with placebo (P < 0.001). The publication includes stratified results of the study on a joint by joint basis and by severity of the diseased joint.
